Ocular Chlamydia Trachomatis Infection: Elimination with Mass Drug Administration

Overview

Journal Expert Rev Anti Infect Ther

Specialty Infectious Diseases

Date 2019 Jan 31

PMID 30698042

Citations 14

Authors

Meraf A Wolle

Sheila K West

Affiliations

Soon will be listed here.

Abstract

Ocular Chlamydia trachomatis infection, the causative agent for trachoma, is responsible for 1.9 million cases of visual loss worldwide. Mass Drug Administration (MDA) with azithromycin to entire trachoma-endemic districts is part of the World Health Organization's public health strategy for trachoma elimination. Areas covered: Background on C. trachomatis and the epidemiology of trachoma are presented, followed by a review of the antibiotics for treatment and the need for a public health approach to trachoma elimination. The effectiveness of mass drug administration is presented, concluding with challenges to trachoma elimination in the future. Expert opinion: MDA using azithromycin is a key component of the public health strategy for trachoma elimination. With high coverage in children, there is good evidence that MDA drops the community pool of infection. There are challenges to trachoma elimination by the year 2020, and the drug donation program for country MDAs will be integral to ongoing efforts.

Citing Articles

Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022.

Sitoe H, Oswald W, Zita F, Fall M, Momade T, Adams M Sci Rep. 2024; 14(1):22842.

PMID: 39406720 PMC: 11480103. DOI: 10.1038/s41598-024-71201-z.

Genomic insights into local-scale evolution of ocular strains within and between individuals in Gambian trachoma-endemic villages.

Ghasemian E, Faal N, Pickering H, Sillah A, Breuer J, Bailey R Microb Genom. 2024; 10(3).

PMID: 38445851 PMC: 10999739. DOI: 10.1099/mgen.0.001210.

Insights into innate immune cell evasion by .

Wang X, Wu H, Fang C, Li Z Front Immunol. 2024; 15:1289644.

PMID: 38333214 PMC: 10850350. DOI: 10.3389/fimmu.2024.1289644.

Gender differences in trachomatous scarring prevalence in a formerly trachoma hyperendemic district in Tanzania.

Wolle M, Munoz B, Mgboji G, Naufal F, Kashaf M, Mkocha H PLoS Negl Trop Dis. 2024; 18(1):e0011861.

PMID: 38277341 PMC: 10817155. DOI: 10.1371/journal.pntd.0011861.

Expanding a photographic grading system for trachomatous scarring.

Nayel Y, Munoz B, Mkocha H, West S, Wolle M Int Health. 2023; 15(Supplement_2):ii25-ii29.

PMID: 38048380 PMC: 10695455. DOI: 10.1093/inthealth/ihad078.

References

West E, Munoz B, Mkocha H, Holland M, Aguirre A, Solomon A . Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci. 2004; 46(1):83-7. PMC: 6853789. DOI: 10.1167/iovs.04-0327. View

Astale T, Sata E, Zerihun M, Nute A, Stewart A, Gessese D . Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia. PLoS Negl Trop Dis. 2018; 12(2):e0006270. PMC: 5833287. DOI: 10.1371/journal.pntd.0006270. View

West S . Trachoma and antibiotic use: the 'A' in SAFE. Expert Rev Anti Infect Ther. 2011; 10(1):75-83. DOI: 10.1586/eri.11.150. View

Darougar S, Jones B, Viswalingam N, Poirier R, Allami J, Houshmand A . Family-based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. Br J Ophthalmol. 1980; 64(4):291-5. PMC: 1043672. DOI: 10.1136/bjo.64.4.291. View

Lee J, Enciso G, Boassa D, Chander C, Lou T, Pairawan S . Replication-dependent size reduction precedes differentiation in Chlamydia trachomatis. Nat Commun. 2018; 9(1):45. PMC: 5752669. DOI: 10.1038/s41467-017-02432-0. View

Elwell C, Mirrashidi K, Engel J . Chlamydia cell biology and pathogenesis. Nat Rev Microbiol. 2016; 14(6):385-400. PMC: 4886739. DOI: 10.1038/nrmicro.2016.30. View

Bailey R, Arullendran P, Whittle H, Mabey D . Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 1993; 342(8869):453-6. DOI: 10.1016/0140-6736(93)91591-9. View

Whitty C, Glasgow K, Sadiq S, Mabey D, Bailey R . Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. Pediatr Infect Dis J. 1999; 18(11):955-8. DOI: 10.1097/00006454-199911000-00003. View

West S, West E, Alemayehu W, Melese M, Munoz B, Imeru A . Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. Arch Ophthalmol. 2006; 124(3):309-14. DOI: 10.1001/archopht.124.3.309. View

10.

Ssemanda E, Levens J, Mkocha H, Munoz B, West S . Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds. PLoS Negl Trop Dis. 2012; 6(3):e1576. PMC: 3308937. DOI: 10.1371/journal.pntd.0001576. View

11.

Lee J, Munoz B, Mkocha H, Gaydos C, Quinn T, West S . The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children. PLoS Negl Trop Dis. 2014; 8(4):e2761. PMC: 3983082. DOI: 10.1371/journal.pntd.0002761. View

12.

Burton M, Holland M, Makalo P, Aryee E, Alexander N, Sillah A . Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet. 2005; 365(9467):1321-8. DOI: 10.1016/S0140-6736(05)61029-X. View

13.

Li J, Donath S, Li Y, Qin D, Prabhakar B, Li P . miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet. 2010; 6(1):e1000795. PMC: 2793031. DOI: 10.1371/journal.pgen.1000795. View

14.

Dize L, West S, Williams J, Van Der Pol B, Quinn T, Gaydos C . Comparison of the Abbott m2000 RealTime CT assay and the Cepheid GeneXpert CT/NG assay to the Roche Amplicor CT assay for detection of Chlamydia trachomatis in ocular samples from Tanzania. J Clin Microbiol. 2013; 51(5):1611-3. PMC: 3647953. DOI: 10.1128/JCM.00519-13. View

15.

Taylor H, Johnson S, PRENDERGAST R, Schachter J, DAWSON C, Silverstein A . An animal model of trachoma II. The importance of repeated reinfection. Invest Ophthalmol Vis Sci. 1982; 23(4):507-15. View

16.

Caldwell H, Wood H, Crane D, Bailey R, Jones R, Mabey D . Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest. 2003; 111(11):1757-69. PMC: 156111. DOI: 10.1172/JCI17993. View

17.

GRAYSTON J, Wang S, Yeh L, Kuo C . Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis. 1985; 7(6):717-25. DOI: 10.1093/clinids/7.6.717. View

18.

HOSHIWARA I, Ostler H, Hanna L, Cignetti F, COLEMAN V, JAWETZ E . Doxycycline treatment of chronic trachoma. JAMA. 1973; 224(2):220-3. View

19.

Wyrick P . Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis. 2010; 201 Suppl 2:S88-95. PMC: 2878585. DOI: 10.1086/652394. View

20.

Nash S, Stewart A, Astale T, Sata E, Zerihun M, Gessese D . Trachoma prevalence remains below threshold in five districts after stopping mass drug administration: results of five surveillance surveys within a hyperendemic setting in Amhara, Ethiopia. Trans R Soc Trop Med Hyg. 2018; 112(12):538-545. PMC: 6255692. DOI: 10.1093/trstmh/try096. View